Skip to main content
. Author manuscript; available in PMC: 2013 May 5.
Published in final edited form as: Liver Transpl. 2012 Sep;18(9):1053–1059. doi: 10.1002/lt.23482

Figure 2.

Figure 2

Liver biochemistries and HCV RNA levels during antiviral therapy. Five months after the first transplant, the patient was started on PEG-IFNα2a (180 μg/week) and ribavirin (1200 mg/day). Despite the partial suppression of HCV RNA, the serum alkaline phosphatase and bilirubin levels continued to rise, and antiviral therapy was discontinued 12 weeks later. After retransplantation, the serum alkaline phosphatase and total bilirubin levels nearly normalized, but they began to rise again with the reemergence of HCV RNA. Four months after the second transplant, the patient was started on DCV (20 mg/day), PEG-IFNα2a (180 μg/week), and ribavirin (800 mg/day). Within 3 weeks of the initiation of therapy, HCV RNA became undetectable, and there were concomitant improvements in the serum alkaline phosphatase and bilirubin levels. After 24 weeks of triple therapy, the patient received another 4 weeks of PEG-IFN/ribavirin consolidation therapy. The patient remained well with HCV RNA undetectable at her last follow-up (32 weeks after the completion of treatment).